Comparative Pharmacology
Head-to-head clinical analysis: ABSTRAL versus DOLENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSTRAL versus DOLENE.
ABSTRAL vs DOLENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
None Documented
None Documented
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Category C
Category C
Opioid Analgesic
Opioid Analgesic